BioLineRx (BLRX) – FDA
-
BioLineRx (BLRX) Reports Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide
-
BioLineRx (BLRX) Announces FDA Approval of APHEXDA in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to BLRX Stock Lookup